This research study will evaluate whether Vitamin D when given with Copaxone reduces the rate of relapse in 2 years. Eligible Participants will be randomized to receive either low dose or high dose vitamin D (oral) with Copaxone. Copaxone and Vitamin D are provided as part of the study.
18-50 years of age with a diagnosis relapsing MS who have had 1 attack and one or two new lesions on MRI in the past year, or have had 2 clinical attacks within the last 2 years which one of was in the past year.
Length of Trial: 2 years
Location of Trial: John L. Trotter MS Center, Washington University School of Medicine
Clinical Trial Sponsor: National MS Society
Susan Fox, Research Patient Coordinator/Professional